FORMATION OF COMPETITIVE POTENTIAL IN THE VECTOR OF INNOVATIVE DEVELOPMENT OF THE PHARMACEUTICAL SECTOR OF UKRAINE IN THE CONDITIONS OF INDUSTRY 4.0

Abstract

The article examines the competitive potential of the pharmaceutical sector of Ukraine in the vector of innovative development in the context of Industry 4.0. The authors prove that competition is the basis of a market economy, contributing to the effectiveness of the self-regulation mechanism. Enterprises are trying to gain competitive advantages, which determines their position in the market. In the context of globalization and technological progress, competitiveness is becoming a key factor for the success of an enterprise, especially in industries such as pharmaceuticals. It is determined that modern requirements for competitiveness are increasing as innovation, speed to market and digitalization become important aspects of competition. The pharmaceutical industry is facing new challenges, in particular the need to adapt to Industry 4.0, which includes smart technologies, automation and digitalization of business processes. Therefore, the introduction of technologies such as artificial intelligence, big data, the Internet of Things, and additive technologies can significantly improve production efficiency, product quality, and the speed of bringing new drugs to market. However, the authors argue that these innovations require significant investments, adaptation of human resources, and data security. Industry 4.0 has a powerful impact on the competitiveness of pharmaceutical companies, as technologies such as additive manufacturing and cyber-physiological systems can significantly improve production processes and supply chain management. At the same time, they create new challenges, in particular, related to the need to train personnel for new technologies and possible social consequences of automation. At the same time, the authors prove that a comprehensive approach, including not only technological but also economic, social and ethical aspects, is important for successful adaptation to new conditions, allowing pharmaceutical companies to ensure sustainable development and strengthen their positions in the domestic and international markets.